Hypertension in Diabetes Study (HDS): II Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertension1993 ;11:309-17.
2.
Mogensen CEACE inhibitors and antihypertensive treatment in diabetes: focus on microalbuminuria and macrovascular disease. JRAAS2001;1:234-9.
3.
Viberti G., Mogensen CE, Groop LC, Pauls JFEffect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA1994;271(4):275-9.
4.
Jafar TH, Schmid CH, Landa M. et al.The ACE Inhibition in Progressive Renal Disease Study Group Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease. A Meta-Analysis of Patient-Level Data Annals of internal medicine2001;135(2):73-87.
5.
UK Prospective Diabetes study group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ1998 ; 317:703-13.
6.
Hannson L., Zanchetti A., Carruthers SGEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal treated (HOT) randomised trial. Lancet1998 ;351(9118):1755-62.
7.
van den Meiracker AH, Man in 't Veld AJ, Admiraal PJ et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?J Hypertens1992;10(8):803-12.
Jorde U., Ennezat PV, Lisker J. et al. Maximally Recommended Doses of Angiotensin-Converting Enzyme (ACE) Inhibitors Do Not Completely Prevent ACE-Mediated Formation of Angiotensin II in Chronic Heart Failure. Circulation2000 ;101:844-6.
10.
Urata H., Healy B., Stewart RW, Bumpus FM, Husain A.Angiotensin II-forming pathways in normal and failing human hearts . Circ Res1990;66:883-90.
11.
Hollenberg NK, Fisher NDL, Price DAPathways for angiotensin II generation in intact human tissue. Evidence for comparative pharmacological interruption of the renin angiotensin system. Hypertension1998; 32:387-92.
12.
Wolny A., Clozel JP, Rein J. et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res1997;80(2):219-27.
13.
Urata H., Kinoshita A., Misono KS, Bumpus FM, Husain A.Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem1990 ;265(36):22348-57.
14.
Califf RM, Cohn JNCardiac protection: evolving role of angiotensin receptor blockers . Am Heart J2000;139(1 Pt 2):S15-22.
15.
Ihara M., Urata H., Kinoshita A. et al. Increased Chymase-Dependent Angiotensin II Formation in Human Atherosclerotic Aorta.Hypertension1999;33(6):1399-405.
16.
Hollenberg NK, Osei SY, Langsang MC, Price DA, Fisher N.Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man. JRAAS2001 ;2:14-8.
17.
MacFadyen RJ , Lees KR, Reid JLTissue and plasma angiotensin converting enzyme and the response to ACE-inhibitor drugs. Br J Clin Pharmacol1991;31:1-13.
18.
Weber KT, Sun Y.Recruitable ACE and tissue repair in the infarcted heart. JRAAS2000;1:295-303.
19.
Dzau VJ, Re R.Tissue angiotensin system in cardiovasular medicine.A paradigm shift . Circulation1994;90(1):449-55.
20.
Rakugi H.,Wang DS, Dzau VJ, Pratt REPotential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation1994;90(1):449-55.
21.
Weinberg MS , Weinberg AJ, Zappe DHEffectively tagetting the renin-angiotensin-aldosterone-system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. JRAAS2000;1:217-33.
22.
Azizi M., Chatellier G., Guyene T.-T, Murieta-Geoffroy D., Menard J.Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation1995;92:825-34.
23.
Azizi M., Linhart A., Alexander J. et al. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens2000;18(8):1139-47.
24.
Fagard R., Lijnen P., Pardaens K., Thijs L., Vinck W.A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension. J Hum Hypertens2001;15:161-7.
25.
Burnier M., Brunner HRAngiotensin II receptor antagonists. Lancet2000; 355: 637-45.
26.
Mazzolai L. , Maillard M., Rossat J., Nussberger J., Brunner HR, Burnier M. Angiotensin II receptor blockade in normal subjects: a direct comparison of three AT1 receptor antagonists . Hypertension1999;33(3):850-5.
27.
Weir MR, Weber MA, Neutel JM, Vendetti J., Michelson EL, Wang RYEfficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators. Am J Hypertens2001;14(6 Pt 1):567-72.
28.
Mogensen CE , Neldam S., Tikkanen I. et al. for the CALM study group.Randomised controlled trial of dual blockade of renin-angiotensin system in patients with Hypertension microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study BMJ2000;321:1440-4.
29.
Dahlöf B., Devereux RB, Julius S. et al. for the LIFE Study Group Characteristics of 9194 Patients With Left Ventricular Hypertrophy. The LIFE Study. Hypertension1998;32:989-97.
30.
Julius S.Long-Term Potential of Angiotensin Receptor Blockade for Cardiovascular Protection in Hypertension: The VALUE Trial. Cardiology1999;91(suppl 1):8-13.
31.
Brenner B for the Renaal study Investigators.RENAAL. Reduction of Endpoints in NIDDM with Angiotensin II Antagonist Losartan American Society of Hypertension 16th Annual Scientific Meeting and Exposition2001.
32.
Lewis EJ et al. IDNT. Irbesartan type II Diabetic Nephropathy Trial. American Society of Hypertension 16th Annual Scientific Meeting and Exposition2001.
33.
Nigel M.Wheeldon, GianCarlo Viberti. Microalbuminuria reduction with valsartan, the MARVALTrial. Am JHypertension14:4(suppl 1):A2.
34.
Parving HH et al. IRMA 2 trial IRbesartan in type 2 diabetes with Microalbuminuria 2. American Society of Hypertension 16th Annual Scientific Meeting and Exposition2001.
35.
Russo D., Pisani A., Balletta MM et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis1999;33(5):851-6.
36.
Kincaid-Smith PS, Fairley KF, Packham DKEffects on blood pressure, proteinuria and renal function of adding a angiotensin receptor antagonist (Candesartan 8 mgs) to an ACE inhibitor in normotensive patients with renal disease. JRAAS2001; 2:50.
37.
Hebert LA, Falkenhain ME, Nahman NS Jr, Cosio FG, O'Dorisio TM. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol1999;19(1):1-6.
38.
Rossing K., Christensen PK, Jensen BR, Parving HHRenoprotective effect of dual blockade of the renin-angiotensin-system (RAS) in type 2 diabetic patients with nephropathy. Abstract. EASD, Glasgow2001.
39.
Ruilope LM, Aldigier JC, Ponticelli C., Oddou-Stock P., Botteri F., Mann JFSafety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens2000 ;18(1):89-95.
40.
Ruzicka M., Yuan B., Harmsen E., Leenen FHThe renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker. Circulation1993;87(3):921-30.
41.
Sadoshima J. , Izumo S.Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res1993;73(3):413-23.
42.
The CONSENSUS Trial Study Group.Effects of enalapril on mortality in severe congestive heart failure . N Engl J Med1987; 316:1429-35.
43.
Pfeffer MA, Braunwald E., Moy LA et al. on behalf of the SAVE investigators.Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med1992;327:669-77.
44.
The SOLVD Investigators.Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med1991;325:293-302.
45.
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet1993;342(8875):821-8.
46.
Kober L.,Torp-Pedersen C., Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333(25):1670-6.
47.
Pitt B., Poole-Wilson PA, Robert Segal R. et al. on behalf of the ELITE II investigators.Effect of losartan compared with captopril on mortality inpatients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet2000;355:1582-7.
48.
Baruch L., Anand I., Cohen IS, Ziesche S., Judd D., Cohn JN; for the Vasodilator Heart Failure Trial (V-HeFT) Study Group.Augmented Short- and Long-Term Hemodynamic and Hormonal Effects of an Angiotensin Receptor Blocker Added to Angiotensin Converting Enzyme Inhibitor Therapy in Patients With Heart Failure. Circulation1999;99:2658-64.
49.
Hamroff G., Katz SD, Mancini D. et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation1999;99(8):990-2.
50.
McKelvie RS , Yusuf S., Pericak D. et al. Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation1999;100:1056-64.
51.
Cohn JN, Tognoni G.Effect of the Angiotensin Receptor Blocker Valsartan on Morbidity and Mortality in Heart Failure: the Valsartan Heart Failure Trial (Val-HeFT) . Circulation2000; 102:2672.
52.
Swedberg K. , Pfeffer M., Granger C. et al. and Charm-Programme Investigators.Candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail1999;5:276-82.
53.
Pfeffer MA, McMurray J., Leizorovicz A. et al. Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design. Am Heart J2000;140:727-34.
54.
Chaturvedi N., Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes.The EUCLID Study Group. EURO-DIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus.Lancet1998;351(9095):28-31.
55.
Campell DJEndogenous angiotensin II levels and the mechanism of action of angiotensin converting enzyme inhibitors and angiotensin receptor type: 1 antagonist. Clin Exp Pharmacol Physiology1996;(suppl 3):S125-31.
56.
Anne Katrin Sjølie.The Diabetic Retinopathy Candesartan Trials (DIRECT) Programme Poster presentation. The 4th International Symposium on Angiotensin II Antagonism. London2001.
